Cargando…
Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo
The IL-6/JAK/STAT pathway is a key signal transduction pathway implicated in the pathogenesis of many human cancers, suggesting that kinase inhibitors targeting JAK/STAT3 may have a broad spectrum of antitumor activity. AZD1480, a pharmacological JAK1/2 inhibitor, exhibits anti-tumor potency in mult...
Autores principales: | Yan, Shuang, Li, Zhijie, Thiele, Carol J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717306/ https://www.ncbi.nlm.nih.gov/pubmed/23531921 |
Ejemplares similares
-
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011) -
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014) -
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B‐Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation
por: Lu, Z., et al.
Publicado: (2017) -
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
por: Gudernova, Iva, et al.
Publicado: (2017) -
AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
por: Couto, Joana P., et al.
Publicado: (2012)